
QuidelOrtho Corp (QDEL) Stock Forecast & Price Target
QuidelOrtho Corp (QDEL) Analyst Ratings
Bulls say
QuidelOrtho Corp has demonstrated strong free cash flow generation, primarily driven by its leadership in point-of-care COVID and flu testing, which positions the company well for future prospects. The merger with Ortho has expanded its product portfolio, allowing QuidelOrtho to effectively compete with larger enterprises in the diagnostics market. Additionally, the transition of legacy operations to the Ortho IT platform is expected to yield long-term cost savings and operational efficiencies, supporting continued margin expansion.
Bears say
QuidelOrtho Corp faces significant challenges that contribute to a negative outlook, particularly due to uncertainty surrounding the launch of its Savanna product and potential loss of market share in the point-of-care and laboratory sectors. The company also risks margin contraction and may struggle with debt repayment, factors that could justify a revised sales multiple at 1.3x, the historical low for comparable non-molecular diagnostics companies. Additionally, ongoing issues related to endemic COVID impacts, ERP consolidation, and lack of clear guidance further compound the risk of achieving long-term financial targets, highlighting potential integration difficulties.
This aggregate rating is based on analysts' research of QuidelOrtho Corp and is not a guaranteed prediction by Public.com or investment advice.
QuidelOrtho Corp (QDEL) Analyst Forecast & Price Prediction
Start investing in QuidelOrtho Corp (QDEL)
Order type
Buy in
Order amount
Est. shares
0 shares